EUVIMEDEUVIMED entdecken
Crossref

Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study

Luigi Gargiulo, Luciano Ibba, Andrea Cortese, Francesco Toso, Carlo A Vignoli, Giovanni Fiorillo, Francesco Piscazzi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

Journal of Drugs in Dermatology · 01.08.2024 · 23 (8) · 632-639

DOI: 10.36849/jdd.7486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Drugs in Dermatology, online erschienen am 01.07.2024. Verfasst von Luigi Gargiulo und 9 weiteren Autor:innen. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 7-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedSeverity of Illness IndexHumansRetrospective StudiesMaleFemaleMiddle AgedTreatment OutcomeAdultAged

Substanzen

guselkumabAntibodies, Monoclonal, Humanized

Zitieren

APA

Gargiulo, L., Ibba, L., Cortese, A., Toso, F., Vignoli, C. A., Fiorillo, G., Piscazzi, F., Valenti, M., Costanzo, A., & Narcisi, A. (2024). Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study. Journal of Drugs in Dermatology, 23(8), 632-639. https://doi.org/10.36849/jdd.7486

Vancouver

Gargiulo L, Ibba L, Cortese A, Toso F, Vignoli CA, Fiorillo G, et al. Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study. Journal of Drugs in Dermatology. 2024;23(8):632-639. doi:10.36849/jdd.7486

BibTeX
@article{Gargiulo2024,
  author = {Gargiulo, Luigi and Ibba, Luciano and Cortese, Andrea and Toso, Francesco and Vignoli, Carlo A and Fiorillo, Giovanni and Piscazzi, Francesco and Valenti, Mario and Costanzo, Antonio and Narcisi, Alessandra},
  title = {Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study},
  journal = {Journal of Drugs in Dermatology},
  year = {2024},
  volume = {23},
  number = {8},
  pages = {632--639},
  doi = {10.36849/jdd.7486}
}
Kostenlos starten →